Wells Fargo initiated coverage of United Therapeutics with an Overweight rating and $309 price target. The market is overly pessimistic on the impact of competition, with shares still not reflecting the growth potential of Tyvaso, but the firm believe Tyvaso in IPF and ralinepag are not priced in at current levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UTHR:
- United Therapeutics price target lowered to $264 from $268 at Ladenburg
- United Therapeutics reports Q3 EPS $5.38, consensus $5.08
- United Therapeutics: First patient enrolled in Phase 3 TETON PPF study
- United Therapeutics to acquire Miromatrix Medical
- UTHR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
